EMC6

Across TCGA pan-cancer cohorts, EMC6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EMC6 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EMC6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EMC6 expression acts as an unfavorable survival marker.

PDAC, GBM, and LUAD are the cancer types where EMC6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.240	0.576	.005	22	view →
GBM	DFS	Quartile	All	0.261	0.602	.008	8	view →
LUAD	DFS	Tertile	All	0.666	1.000	.037	2	view →
CCRCC	OS	Tertile	III,IV	0.513	0.952	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EMC6–PDAC (DFS)

Open the PDAC breakdown →